Jump to content

Harrison Stafford

Legacy Members
  • Posts

    2852
  • Joined

  • Last visited

Everything posted by Harrison Stafford

  1. Would you ask her to buy some calls on IBRX?
  2. So, after going “all in” with my 2010 Lexus RX 350, yesterday, I’m stopped at a red light and get rear ended in a multiple car accident as the car behind me was pushed into my car. It smashed my right rear bumper, the hatch won’t open, and there’s lights flashing on the dashboard like a Christmas tree. And the auto insurance policy of the guy who caused the accident had lapsed. Two week ago as I hand washed my car for the first time in 15 years, in the back of my mind I thought something like this would happen. Furk. BUT, my wife and I weren’t killed or seriously injured, the car was still drivable, I wasn’t driving a new Porsche Cayenne, and I can still achieve my 2025 financial goals. ‘‘Tis but a flesh wound.
  3. If a receiver gets two hands on the ball, he >must< make the catch.
  4. Save us, Josh Allen.
  5. Every fan who thinks Kansas City has received special treatment this season should chip in and help him pay that fine.
  6. And that’s what the NFL wants.
  7. We survived the first quarter. Everyone take a deep breath.
  8. The Texans need to get off to a decent start and let ‘er rip. No one expects us to win this game, so we’ve got nothing to lose. Fake punts, double reverse passes….throw everything in the playbook at ‘em. LFG!
  9. When ImmunityBio’s, Anktiva, becomes the mainstay treatment for every kind of cancer, their CEO, Patrick Soon-Shiong, wins the Nobel Prize for Medicine, and I have enough money to buy all you heathens new cars, this will all seem like a dream……albeit, a bad dream at the moment. 27,800 shares with a cost basis of $9.77.
  10. ImmunityBio Shares Climb After Company Previews FY25 Regulatory Advances Published: Jan. 16, 2025 at 12:36 p.m. ET By Owen Tucker-Smith ImmunityBio shares rose after the company said it planned to submit multiple treatments for FDA commercial approval in 2025. Shares of the San Diego-based biotechnology company were recently up 16% to $2.77. The stock is down more than 57% over the last six months, and more than 28% over the last year. The company said Wednesday evening that it would submit a supplemental biologics license application, or BLA, for a treatment that targets a type of bladder cancer. BLAs, if approved by the FDA, allow companies to sell their products across state lines. The company said it would submit another BLA in 2025 for a treatment of patients with a certain type of lung cancer. The company said that a Phase 2b study had indicated positive results for patients for whom first and second treatment attempts have been unsuccessful when they used the company's Anktiva drug in combination with other inhibitors. Executive Chairman Patrick Soon-Shiong characterized improved outcomes for these types of lung cancer as an "unmet need." Soon-Shiong also owns the Los Angeles Times. ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of BCG in collaboration with the Serum Institute of India, and noted that there is currently a shortage of the drug IBRX +.65 to $3.04.
  11. Lol. Unfortunately, I’m so underwater in some of my other positions that I have a ways to go before I’m back in black. Hope springs eternal.
  12. EOSE + 1.12 to $6.33. Another 52 wk high. Holding 20,000 shares at avg cost of $1.98.
  13. I may be in the minority, but I’m pulling for you ying yangs vs ND.
  14. What is remarkable is the Texans didn’t collapse after this play turning the momentum right around with the blocked extra point and the two point conversion.
  15. Turn out the lights The party’s over
  16. I am not believing this.
×
×
  • Create New...